Drug Trial Radar · NCT00368030
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
545
Actual
Start
Jan 2004
Primary completion
Oct 2004
Study completion Oct 2004
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
Conditions
- Insomnia
- Depressive Disorder, Major
Interventions
EszopicloneDrug
Eszopiclone 3 mg QD
PlaceboOther
Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean subjective wake time after sleep onset (WASO)Time frame: 1 week
Locations
65 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Peoria, Arizona
Site not named
Tucson, Arizona
Site not named
Fayetteville, Arkansas
Site not named
Garden Grove, California
Site not named
Irvine, California
Site not named
Northridge, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
Wheat Ridge, Colorado
Site not named
New Britian, Connecticut
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
North Miami, Florida
Site not named
St. Petersburg, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Decatur, Georgia
Site not named
Smyrna, Georgia
Site not named
Boise, Idaho
Site not named
Overland Park, Kansas
Site not named
Rockville, Maryland
Site not named
Boston, Massachusetts
Site not named
Braintree, Massachusetts
Site not named
Brighton, Massachusetts
Site not named
Brockton, Massachusetts
Site not named
Cambridge, Massachusetts
Site not named
Watertown, Massachusetts
Site not named
Farmington Hills, Michigan
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Clementon, New Jersey
Site not named
Morestown, New Jersey
Site not named
Lawerence, New York
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Durham, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Bismarck, North Dakota
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.